Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002173 · ClinicalTrials.gov registry record · NA
An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.
A NA study of HIV Infections, sponsored by The Immune Response Corporation.
- Completed
- Registry status
- NA
- Development phase
- 1
- Study location
NCT00002173: Completed NA study of HIV Infections, sponsored by The Immune Response Corporation.
NCT00002173 is a NA study of HIV Infections that has completed, run by The Immune Response Corporation. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002173, a NA study of HIV Infections, has completed, sponsored by The Immune Response Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 1
- Study location
Study Summary
To provide an alternative therapy to HIV-infected patients for whom there is no comparable or satisfactory alternative drug or therapy available.
Conditions Studied
Interventions
- BIOLOGICAL HIV-1 Immunogen
Study Locations (1)
California
- Immune Response Corp - Carlsbad
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002173
The ClinicalTrials.gov registry entry for NCT00002173 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is The Immune Response Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which HIV-1 Immunogen is the first listed.
NCT00002173 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00002173 about?
NCT00002173 is a clinical study titled "An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.". To provide an alternative therapy to HIV-infected patients for whom there is no comparable or satisfactory alternative drug or therapy available.
What is the current status of trial NCT00002173?
This trial is currently completed. It is a NA study.
What conditions does trial NCT00002173 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002173?
The interventions under investigation include: HIV-1 Immunogen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002173?
This trial is sponsored by The Immune Response Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002173 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.